SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.

Shijiazhuang Yiling Pharmaceutical Co., Ltd.

002603

CNE1000015S0

Pharmaceuticals

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
19.58 ^CNY	+0.67%		+1.40%	-15.13%

Apr. 26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
Apr. 26	Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023

July 11, 2023 at 03:36 pm EDT

Shijiazhuang Yiling Pharmaceutical Co., Ltd. announced 2022 final profit distribution plan to be implemented (A shares) cash dividend per 10 shares (tax included) of CNY 5.00000000. Record date: 14 July 2023; Ex-date: 17 July 2023; Payment date: 17 July 2023.

Latest news about Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 26	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Apr. 26	CI
Yiling Pharmaceutical Gets Nod for China Clinical Trial of Tracheobronchitis Drug	Dec. 06	MT
Yiling Pharmaceutical's Lianhua Qingke Tablets Gets Nod to Become Over-the-Counter Drug; Shares Up 4%	Nov. 23	MT
Yiling Pharmaceutical Gets Nod to Trial Huoxia Cold Granules	Nov. 17	MT
Yiling Pharmaceutical Presents Clinical Data on Cardiovascular Drug at Beijing Conference	Nov. 17	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023	23-10-26	CI
Yiling Pharmaceutical Gets Green Light to Trial Acute Myeloid Leukemia Drug	23-10-24	MT
Yiling Pharmaceutical Gets Greenlight to Trial G201-Na Capsules	23-10-12	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-28	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Announces Implementation of Cash Dividend for 2022, Payable on 17 July 2023	23-07-11	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Approves Cash Dividend for 2022	23-05-22	CI
Yiling Pharma's Hypertension Drug Passes Regulatory Evaluation in China	23-05-15	MT
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Proposes Final Cash Dividend for 2022	23-04-26	CI
Shijiazhuang Yiling Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-04-25	CI
Yiling Pharma Wins Nod to Trial Prostate Cancer Drug	23-04-05	MT
Yiling Pharma Unit Gets Marketing Rights of Rujietai Capsules	23-03-02	MT
Shijiazhuang Yiling Pharma Appoints Founder as Honorary Chairman	23-02-28	MT
Yiling Pharma Gets Regulatory Nod for Traditional Chinese Medicine	23-02-03	MT
Yiling Pharma’s Antibiotic Passes Consistency Test	23-02-03	MT
Shijiazhuang Yiling’s Depression Drug Included in China’s Medical Insurance Catalog	23-01-20	MT
Yiling Pharma’s Traditional Chinese Medicine Added to Government's Recommended Drugs For COVID-19	23-01-08	MT
Gloom and boom: Fund managers' top picks for 2023	23-01-03	RE
Chinese Shares End Year With Modest Gains; Two Shenzhen Debutants Post Mixed Results	22-12-30	MT
Health Care Tick Down on Growth Fears -- Health Care Roundup	22-12-27	DJ

Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Duration

Period

Chart Shijiazhuang Yiling Pharmaceutical Co., Ltd.

More charts

Company Profile

SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the research and development, manufacture and distribution of pharmaceuticals. The Company mainly provides cardiovascular and cerebrovascular drugs and anti-cold drugs. The Company also provides food and beverage products. The Company distributes its products within domestic market and to overseas markets.

Sector

Pharmaceuticals

Calendar

2024-08-26 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Shijiazhuang Yiling Pharmaceutical Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

19.58 CNY

Average target price

24.16 CNY

Spread / Average Target

+23.39%

Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-15.13%	4.51B
DONG-E-E-JIAO CO.,LTD.	+35.04%	5.92B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.75%	3.15B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+2.14%	3.1B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-6.82%	2.42B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+47.87%	1.97B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-7.89%	1.68B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	+0.09%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-12.97%	1.53B
ZHEJIANG JOLLY PHARMACEUTICAL CO.,LTD	+33.40%	1.38B

Alternative Medicine